Numbers and cellular origin of microparticles and microparticles with surface-bound C3 and/or C9
| Agonist . | Total amount of microparticles, 103/ml . | CD42b-positive microparticles, 103/mL . | CD38-positive microparticles, 103/mL . | CD66-positive microparticles, 103/mL . | |||
|---|---|---|---|---|---|---|---|
| C3-positive . | C9-positive . | C3-positive . | C9-positive . | C3-positive . | C9-positive . | ||
| Stx1 | 1992* (1068-2395) | 702* (259-871) | 717* (268-870) | 336* (245-528) | 312* (236-598) | 0.3NS (0.2-0.4) | 0.2NS (0.1-0.4) |
| Stx1B | 1301* (967-2364) | 766* (505-864) | 721* (478-819) | 264* (136-479) | 351* (116-519) | 0.1NS (0.1-0.2) | 0.2NS (0.1-0.3) |
| Stx2 | 1341* (1145-2003) | 845* (745-991) | 839* (776-990) | 421* (155-638) | 455* (170-685) | 0.3NS (0.1-0.5) | 0.2NS (0.1-0.3) |
| O157LPS | 1749* (1487-2128) | 859* (528-1047) | 822* (512-1055) | 487* (300-739) | 499* (281-732) | 1.4* (1.0-1.7) | 1.5* (0.9-1.8) |
| O111:B4LPS | 1351* (525-2970) | 805* (499-1003) | 831* (514-1019) | 415* (178-880) | 453* (185-848) | 1.4* (0.5-1.8) | 1.5* (0.5-1.7) |
| Stx2/O157LPS | 2015* (1632-2785) | 1466* (811-1895)† | 1414* (817-1861)† | 312* (269-735) | 328* (275-761) | 1.9* (1.5-2.2) | 1.8* (1.4-2.3) |
| Stx2/O111:B4LPS | 1430* (931-2623) | 994* (725-1468) | 1218* (802-1865) | 286* (251-626) | 295* (268-640) | 1.7* (1.5-1.9) | 1.6* (1.2-1.9) |
| PBS | 240 (153-565) | 99 (54-202) | 85 (48-212) | 67 (34-154) | 63 (28-151) | 0.3 (0.1-0.3) | 0.2 (0.1-0.3) |
| Agonist . | Total amount of microparticles, 103/ml . | CD42b-positive microparticles, 103/mL . | CD38-positive microparticles, 103/mL . | CD66-positive microparticles, 103/mL . | |||
|---|---|---|---|---|---|---|---|
| C3-positive . | C9-positive . | C3-positive . | C9-positive . | C3-positive . | C9-positive . | ||
| Stx1 | 1992* (1068-2395) | 702* (259-871) | 717* (268-870) | 336* (245-528) | 312* (236-598) | 0.3NS (0.2-0.4) | 0.2NS (0.1-0.4) |
| Stx1B | 1301* (967-2364) | 766* (505-864) | 721* (478-819) | 264* (136-479) | 351* (116-519) | 0.1NS (0.1-0.2) | 0.2NS (0.1-0.3) |
| Stx2 | 1341* (1145-2003) | 845* (745-991) | 839* (776-990) | 421* (155-638) | 455* (170-685) | 0.3NS (0.1-0.5) | 0.2NS (0.1-0.3) |
| O157LPS | 1749* (1487-2128) | 859* (528-1047) | 822* (512-1055) | 487* (300-739) | 499* (281-732) | 1.4* (1.0-1.7) | 1.5* (0.9-1.8) |
| O111:B4LPS | 1351* (525-2970) | 805* (499-1003) | 831* (514-1019) | 415* (178-880) | 453* (185-848) | 1.4* (0.5-1.8) | 1.5* (0.5-1.7) |
| Stx2/O157LPS | 2015* (1632-2785) | 1466* (811-1895)† | 1414* (817-1861)† | 312* (269-735) | 328* (275-761) | 1.9* (1.5-2.2) | 1.8* (1.4-2.3) |
| Stx2/O111:B4LPS | 1430* (931-2623) | 994* (725-1468) | 1218* (802-1865) | 286* (251-626) | 295* (268-640) | 1.7* (1.5-1.9) | 1.6* (1.2-1.9) |
| PBS | 240 (153-565) | 99 (54-202) | 85 (48-212) | 67 (34-154) | 63 (28-151) | 0.3 (0.1-0.3) | 0.2 (0.1-0.3) |
Data are expressed as median and (range) of circulating microparticles positive for each membrane-specific marker per milliliter. Values were derived from six different experiments.
NS indicates not significant.
P < .001 comparing microparticles released in whole blood stimulated with Stx2, Stx 1, Stx1B, LPS or Stx/LPS with PBS-treated whole blood.
Costimulation of whole blood with Stx2 and O157LPS induced an increase in platelet microparticles with surface-bound C3 or C9 compared with Stx2 (P < .001) or O157LPS (P < .001) alone, while no significant increase was noted on monocyte microparticles in whole blood costimulated with Stx2 and O157LPS compared with each agonist alone.